Project Details
Description
Development of an oral formulation of a metabolite of ketamine, 2R,6R-HNK, as a next-generation antidepressant.
| Status | Finished |
|---|---|
| Effective start/end date | 9/24/18 → 10/31/20 |
Funding
- NATIONAL INSTITUTES OF HEALTH (NIH)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.